Announcements & Circulars-Alphamab Oncology

English 中文简体中文繁体

English 中文简体中文繁体

Investors

Information Disclosure

Listing Documents

Financial Reports

Announcements & Circulars

Company Presentation

Corporate Governance

Stock Information

Corporate Communications

Email Subscription

Announcements & Circulars

The announcement begins in December 2019

ADOPTION OF THE RESTRICTED SHARE AWARD SCHEME 2021-03-23
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020 2021-03-23
DATE OF BOARD MEETING 2021-03-11
VOLUNTARY ANNOUNCEMENT - IND APPROVAL RECEIVED FOR A PHASE II CLINICAL TRIAL OF KN046 IN THE U.S. 2021-03-08
Monthly Return of Equity Issuer on Movements in Securities for the month ended 28 February 2021 2021-03-04
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 January 2021 2021-02-05
VOLUNTARY ANNOUNCEMENT – ABSTRACTS ON CLINICAL DATA FROM PHASE II CLINICAL STUDY OF KN046 IN PATIENTS WITH ADVANCED NSCLC AND PRELIMINARY RESULTS OF KN046 IN PATIENTS WITH RARE THORACIC TUMORS FOR PRESENTATION AT WCLC 2020 2021-01-13
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 December 2020 2021-01-08
VOLUNTARY ANNOUNCEMENT - INCLUSION OF THE SHARES OF THE COMPANY IN THE HONG KONG STOCK CONNECT LIST UNDER THE SHENZHEN-HONG KONG STOCK CONNECT 2020-12-28
VOLUNTARY ANNOUNCEMENT - THE COMBINATION THERAPY OF KN026 AND KN046 WAS GRANTED ORPHAN DRUG DESIGNATION BY THE U.S. FDA 2020-12-23

18 19 20 21 22 23 24